Erica K. Barkei

Erica K. Barkei

Auto-generated profile, based on publicly available information

Erica K. Barkei

US Military HIV Research Program, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, United States

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2022 in Science Translational Medicine
Verified
Journal Article
Open access
GJGordon Joyce
Gordon Joyce
HKHannah A. D. King
Hannah A. D. King
IEInes Elakhal-Naouar
Ines Elakhal-Naouar
AAAslaa Ahmed
Aslaa Ahmed
KPKristina K. Peachman
Kristina K. Peachman
KMKayvon Modjarrad
Kayvon Modjarrad
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants stresses the continued need for next-generation vaccines that confer broad protection against coronavirus disease 2019. We developed and evaluated an adjuvanted SARS-CoV-2 spike ferritin nanoparticle (SpFN) vaccine in nonhuman primates. High-dose (50-μg) SpFN vaccine, given twice 28 days apart, induced a T helper cell 1 (T H 1)–biased CD4 T H response and elicited neutralizing antibodies against SARS-CoV-2 wild type and variants of concern, as well as against SARS-CoV-1. These potent humoral and cell-mediated immune responses translated into rapid elimination of replicating virus in the upper and lower airways and lung parenchyma of nonhuman primates after high-dose SARS-CoV-2 respiratory challenge. The immune response elicited by SpFN vaccination and resulting efficacy in nonhuman primates support the utility of SpFN as a vaccine candidate for SARS-causing betacoronaviruses.

28 October 2021 in npj Vaccines
Verified
Journal Article
Open access
PDF file
KWKathryn McGuckin Wuertz
Kathryn McGuckin Wuertz
EBErica K. Barkei
Erica K. Barkei
WCWei-Hung Chen
Wei-Hung Chen
EMElizabeth J. Martinez
Elizabeth J. Martinez
ILInes Lakhal-Naouar
Ines Lakhal-Naouar
KMKayvon Modjarrad
Kayvon Modjarrad
The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a SARS-CoV-2 spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferred protection against the Alpha (B.1.1.7), and Beta (B.1.351) VOCs in Syrian golden hamsters. SpFN-ALFQ was administered as either single or double-vaccination (0 and 4 week) regimens, using a high (10 μg) or low (0.2 μg) dose. Animals were intranasally challenged at week 11. Binding antibody responses were comparable between high- and low-dose groups. Neutralizing antibody titers were equivalent against WA1, B.1.1.7, and B.1.351 variants following two high dose vaccinations. Dose-dependent SpFN-ALFQ vaccination protected against SARS-CoV-2-induced disease and viral replication following intranasal B.1.1.7 or B.1.351 challenge, as evidenced by reduced weight loss, lung pathology, and lung and nasal turbinate viral burden. These data support the development of SpFN-ALFQ as a broadly protective, next-generation SARS-CoV-2 vaccine.

21 March 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
HKHannah A. D. King
Hannah A. D. King
VDVincent Dussupt
Vincent Dussupt
LMLetzibeth Mendez-Rivera
Letzibeth Mendez-Rivera
BSBonnie M. Slike
Bonnie M. Slike
UTUrsula Tran
Ursula Tran
DBDiane L. Bolton
Diane L. Bolton
Introduction: Antibody therapeutic strategies have served an important role during the COVID-19 pandemic, even as their effectiveness has waned with the emergence of escape variants. Here we sought to determine the concentration of convalescent immunoglobulin required to protect against disease from SARS-CoV-2 in a Syrian golden hamster model.Methods: Total IgG and IgM were isolated from plasma of SARS-CoV-2 convalescent donors. Dose titrations of IgG and IgM were infused into hamsters 1 day prior to challenge with SARS-CoV-2 Wuhan-1.Results: The IgM preparation was found to have ~25-fold greater neutralization potency than IgG. IgG infusion protected hamsters from disease in a dose-dependent manner, with detectable serum neutralizing titers correlating with protection. Despite a higher in vitro neutralizing potency, IgM failed to protect against disease when transferred into hamsters.Discussion: This study adds to the growing body of literature that demonstrates neutralizing IgG antibodies are important for protection from SARS-CoV-2 disease, and confirms that polyclonal IgG in sera can be an effective preventative strategy if the neutralizing titers are sufficiently high. In the context of new variants, against which existing vaccines or monoclonal antibodies have reduced efficacy, sera from individuals who have recovered from infection with the emerging variant may potentially remain an efficacious tool.